GlassScriptPhysician profile
Sinan Kadayifci
NPI 1730168246
$1,880.51
in general payments reported to CMS, 2019-2025
14 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2021: $356 · 2022: $427 · 2023: $201 · 2024: $326 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $489.83 | 2021-2025 | Symplicity G3, Aurora Ev-Icd Mri Surescan, Micra |
| Boston Scientific Corporation | $294.14 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $133.27 | 2023 | Camzyos |
| Impulse Dynamics (USA) INC. | $131.89 | 2021 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.25 | 2022 | |
| Heartflow, INC. | $122.95 | 2024 | |
| Edwards Lifesciences Corporation | $120.78 | 2019 | |
| Philips North America LLC | $112.68 | 2024 | (Ao0) Igt Devices Intracardiac |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.59 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $48.15 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $24.73 | 2023 | |
| Abbott Laboratories | $22.19 | 2024 | Cardiomems |
| Novo Nordisk INC | $20.06 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinan Kadayifci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.